Inactive Instrument
CARDIUM THRPTCS Stock NYSE
Stocks
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
NYSE
|
||
| - USD | - |
|
| 30/03/22 | Gene Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt | CI |
| 04/09/21 | Gene Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020 | CI |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 72 | 22/12/2003 | |
James Grainer
DFI | Director of Finance/CFO | 71 | 22/05/2020 |
Ronald Shebuski
CTO | Chief Tech/Sci/R&D Officer | 73 | 22/05/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
James Grainer
CHM | Chairman | 71 | 22/05/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +4.16% | +4.16% | +49.37% | +94.17% | 74.68B | |
| -13.33% | -13.00% | +6.55% | +56.79% | 58.7B | |
| -1.84% | +1.21% | +4.15% | +32.26% | 48.36B | |
| -5.05% | -5.61% | +306.40% | +663.02% | 43.05B | |
| -0.71% | -2.37% | +26.89% | +27.56% | 42.48B | |
| -4.12% | -2.16% | -0.02% | +103.15% | 41.39B | |
| -0.11% | +1.96% | +9.19% | +52.66% | 31.29B | |
| -1.62% | -3.94% | -12.47% | -14.89% | 23.93B | |
| -2.72% | -9.52% | -39.28% | +300.86% | 22.22B | |
| Average | -2.66% | -2.18% | +38.98% | +146.17% | 42.9B | |
| Weighted average by Cap. | -2.64% | -1.56% | +45.90% | +139.57% |
Employees
-
Select your edition
All financial news and data tailored to specific country editions
